Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transplantation for autoimmune hepatitis.

James Neuberger1

  • 1Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom. J.M.Neuberger@bham.ac.uk

Seminars in Liver Disease
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An international multidisciplinary consensus statement on laparoscopic liver biopsy.

Cell reports. Medicine·2026
Same author

Toward Reducing Inequity in Transplantation of the Socioeconomic Disadvantaged: A Glimmer of Hope?

Transplantation·2026
Same author

Guidelines from the expert advisory committee on the Safety of Blood, Tissues and Organs (SaBTO) on patient consent and shared decision-making for blood transfusion.

British journal of haematology·2025
Same author

What price for increasing blood safety?

Lancet (London, England)·2025
Same author

Strong or Weak Consent in Medical Law? Identifying the Values Protected in Transplantation Medicine in Europe.

European journal of health law·2025
Same author

We should implement electronic blood management systems across the UK to improve blood transfusion safety.

BMJ (Clinical research ed.)·2025

Liver transplantation offers good survival for autoimmune hepatitis (AIH) patients, but predicting transplant timing and managing recurrent or de novo AIH post-transplant remain challenging, often requiring long-term immunosuppression.

Area of Science:

  • Hepatology and Immunology
  • Transplantation Medicine

Background:

  • Autoimmune hepatitis (AIH) is a recognized indication for liver transplantation, achieving 5- and 10-year survival rates near 75%.
  • Predicting the optimal timing for liver transplantation in AIH patients is challenging due to the unpredictable progression of end-stage liver disease.
  • Post-transplant, patients face risks including recurrent AIH and de novo AIH in the allograft, necessitating ongoing management.

Purpose of the Study:

  • To define the characteristics and management of recurrent and de novo autoimmune hepatitis (AIH) after liver transplantation.
  • To evaluate the long-term outcomes and challenges associated with liver transplantation for AIH.
  • To highlight the complexities in managing immunosuppression and rejection in AIH liver transplant recipients.

Main Methods:

Related Experiment Videos

  • Review of clinical data and outcomes for patients who underwent liver transplantation for autoimmune hepatitis (AIH).
  • Analysis of recurrence rates, de novo disease development, and graft survival.
  • Assessment of treatment responses to corticosteroids and increased immunosuppression.

Main Results:

  • Recurrent autoimmune hepatitis (AIH) post-transplantation is a significant concern, though not always well-characterized.
  • De novo AIH can develop in the liver allograft, often responding to increased immunosuppression, but graft failure can occur.
  • Patients transplanted for AIH exhibit a higher risk of acute and chronic rejection, making immunosuppression withdrawal unlikely.

Conclusions:

  • Liver transplantation is a viable option for autoimmune hepatitis (AIH), but requires careful timing and management of post-transplant complications.
  • Recurrent and de novo AIH present distinct challenges, impacting graft survival and necessitating tailored immunosuppressive strategies.
  • Long-term immunosuppression is typically required for AIH liver transplant recipients due to persistent risks of rejection and disease recurrence.